ClinicalTrials.gg
TerminatedNCT01732510Updated Mar 15, 2019Results posted

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

A Phase 1 interventional study of MK-8226 and Placebo in Atopic Dermatitis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was prematurely stopped due to business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in participants with moderate to severe atopic dermatitis. Part 1 (multiple rising dose study) objectives were to find the maximum tolerated dose (MTD) of MK-8226 and to assess safety and PK. Part 2 objectives were to determine safety, PK, and preliminary efficacy. Part 3 objectives were to further define safety and PK, and explore MK-8226 PK/PD to model the optimal dose range for future studies. The study was terminated early due to business reasons on 08 May 2014; final results from an analysis for Part 1 (efficacy, PK, safety, immunogenicity) and Part 2 (safety, immunogenicity) are summarized.

Read the detailed description

Part 1 of the study is a multiple rising dose assessment of the safety, tolerability, and pharmacokinetics of MK-8226 for a period of 12 weeks followed by a 20-week off-treatment follow-up period.

Part 2 of the study is an assessment of the safety, tolerability, and efficacy of MK-8226 for 12 weeks followed by a 20-week off-treatment follow-up period.

In Part 3 of the study, participants will be treated with MK-8226 for a period of 12 weeks followed by a 20-week off-treatment follow-up period to evaluate pharmacokinetic and pharmacokinetic correlations to assist with modeling the dose range planned for further studies.

02

Conditions studied

  • Atopic Dermatitis

Browse trials for

03

In context

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

This study's enrollment of 65 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >=40 kg
  • Clinical diagnosis of atopic dermatitis for at least 6 months prior
  • Candidate for systemic or phototherapy (i.e., failed topical treatment)
  • Moderate-to-severe disease as defined by Body Surface Area (BSA) ≥10%, EASI ≥12, and IGA ≥3
  • No abnormality on
  • No history of active or latent tuberculosis (TB) and no signs or symptoms suggestive of TB
  • No history of active or latent TB and no signs or symptoms suggestive of TB
  • History of inadequate response to a stable (≥ 1 month) regimen of topical or calcineurin inhibitors within 3 months before the screening visit

Exclusion criteria

Exclusion Criteria:

  • Concurrent significant skin disease
  • Any significant organ dysfunction within 6 months prior
  • History of heart disease
  • History of neoplastic disease
  • Positive for , , or (HIV)
  • Infection requiring oral antibiotics within 2 weeks prior
  • Receipt of a within 4 weeks prior
  • Inability to refrain from topical or systemic therapy during course of the study
  • Had major surgery or donated or lost >=1 unit of blood within 4 weeks prior
  • Participation in another study within 4 weeks prior
  • Current or regular user of illicit drugs or a history of drug or alcohol abuse within 1 year prior
  • Pregnant, breast-feeding, or anticipated to conceive during the course of the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Part 1: MK-8226 0.3 mg/kg

    MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.

    Drug: MK-8226

  • Experimental
    Part 1: MK-8226 1 mg/kg

    MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.

    Drug: MK-8226

  • Experimental
    Part 1: MK-8226 3 mg/kg

    MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.

    Drug: MK-8226

  • Experimental
    Part 1: MK-8226 10 mg/kg

    MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.

    Drug: MK-8226

  • Placebo comparator
    Part 1: Placebo (pooled)

    Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.

    Drug: Placebo

  • Experimental
    Part 2: MK-8226 3 mg/kg

    MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.

    Drug: MK-8226

  • Placebo comparator
    Part 2: Placebo

    Placebo administered IV every 2 weeks for a period of 12 weeks.

    Drug: Placebo

Interventions

  • MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.

  • DrugPlacebo

    Placebo administered IV every 2 weeks for a period of 12 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced at Least One Adverse Event

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to 32 Weeks

  2. Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

    Time frame: Up to 12 Weeks

  3. Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 1

    Reduction from baseline in EASI at Week 12 (interim analysis data). The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Plasma Chemokine (C-C Motif) Ligand 17 (CCL17) Level in Study Part 2

    CCL17 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL17 are increased in allergic disease states.

    Time frame: Baseline, 48 Hours, Week 2, Week 4, Week 12, Week 16

  2. Plasma Chemokine (C-C Motif) Ligand 22 (CCL22) Level in Study Part 2

    CCL22 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL22 are increased in allergic disease states.

    Time frame: Baseline, 48 Hours, Week 2, Week 4, Week 12, Week 16

  3. Area Under the Concentration-time Curve of MK-8226 From Time 0 to Tau (AUC0-tau) Following Multiple Intravenous Dose Administration

    AUC(0-tau) defined as AUC from time zero to tau where tau is the dosing interval (312 hours) was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

    Time frame: Days 1, 3, 5, 9, 14, 70, 72, 74, 84

  4. AUC From Time 0 to Last Measurement (AUC0-last) of MK-8226 Following Multiple Intravenous Dose Administration

    AUC0-last defined as AUC up to the last measured concentration was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

    Time frame: Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224

  5. Maximum Serum Concentration (Cmax) of MK-8226 Following Multiple Dose Intravenous Administration

    Cmax was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

    Time frame: Days 1, 3, 5, 9, 14, 70, 72, 74, 84

  6. Clearance (CL) of MK-8226 Following Multiple Dose Intravenous Administration

    CL, the volume of plasma cleared of drug per unit time, was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 28 (incl. predose), 42 (incl. predose), 56 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

    Time frame: Days 1, 3, 5, 9, 14, 28, 42, 56, 70, 72, 74, 84

  7. Volume of Distribution (Vd) of MK-8226 Following Multiple Intravenous Administration

    Vd, a theoretical approximation of degree to which the drug distributes in body tissue rather than plasma (higher Vd indicates greater tissue distribution), was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

    Time frame: Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224

  8. Terminal Half Life (t1/2) of MK-8226 Following Multiple Dose Intravenous Administration

    t1/2, the time needed for the concentration of drug to reach half the initial concentration, was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

    Time frame: Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224

  9. Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 2

    The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).

    Time frame: Baseline, Week 4, Week 8, Week 24

  10. Percentage of Participants With an Investigator Global Assessment (IGA) Score of Clear or Almost Clear in Study Part 2

    Percentage of participants achieving an IGA of atopic dermatitis of "clear-0" or "almost clear-1". The IGA is a six-point scale measuring the severity of disease at time of physical examination of the participant by the physician. The IGA is scored 0 (Clear) to 5 (Very severe disease).

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 24

  11. Change From Baseline in the Scoring Atopic Dermatitis Scale (SCORAD) in Study Part 2

    The SCORAD index scale combines 1) intensity of six lesion characteristics (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness) as assessed by the physician on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities) along with 2) subjective symptoms of pruritus and sleep disturbance as reported by the patient on a visual analog scale (VAS) from 1 to 10 cm (increasing severity). Physician assessment of affected areas in each region is made as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The final SCORAD index score, ranging from 0 (absent disease) to 103 (severe disease), is calculated according to the weighted formula: (0.2 x area) + (3.5 x \[sum of intensity score for each of the 6 items\]) + participant's subjective score.

    Time frame: Baseline, Week 4, Week 12, Week 24

  12. Change From Baseline in Participant Pruritus in Study Part 2

    Skin pruritus (itching) is a typical characteristic of atopic dermatitis. Participant subjective assessment of pruritus (component of SCORAD) is rated on a VAS ranging from 1 to 10 cm (increasing severity).

    Time frame: Baseline, Week 4, Week 12, Week 24

  13. Change From Baseline in Participant Sleep Disturbance in Study Part 2

    Sleep disturbance (sleep loss, disruption, or interference) due to unremitting pruritus and other causes is a quality of life issue in moderate to severe atopic dermatitis. Participant subjective assessment of sleep disturbance (component of SCORAD) over the past 3 days is rated on a VAS ranging from 1 to 10 cm (increasing severity).

    Time frame: Baseline, Week 4, Week 12, Week 24

  14. Number of Participants Requiring As-Needed Oral Antihistamines as Rescue Medication in Study Part 2

    Oral antihistamines (i.e., diphenhydramine, acrivastine fenistil) were provided as as-needed rescue medication for severe pruritus.

    Time frame: Up to Week 12

  15. Percentage of Participants With >=50% Improvement in EASI Score

    The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).

    Time frame: Baseline, Week 12, Week 24

  16. Number of Participants Positive for Anti-Drug Antibody (ADA) Formation

    Testing for ADA positivity and neutralizing response and antibody titre quantification are performed with blood (serum) samples collected at baseline (Day 1 predose) and Days 14, 28, 42, 56, 74, 112, and 224. Neutralizing response refers to ADA neutralizing interference with study drug assessed in vitro. Non-Treatment emergent ADA refers to presence of ADAs (as determined by assay) in the absence of treatment with study drug (i.e., at predose).

    Time frame: Days 1 (predose) and Days 14, 28, 42, 56, 74, 112, and 224

Other outcomes

  1. Change From Baseline in the Participant's Global Impression of Disease Status in Study Part 2

    Participant subjective impression of improvement of his/her disease condition is scored on a six-point scale: 0 (Clear) to 5 (Very severe disease).

    Time frame: Baseline, Week 4, Week 12, Week 24

07

Results

Posted Jun 9, 2016

Participant flow

Participant flow — Overall Study
MilestonePart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: Placebo
Started998108138
Completed8445300
Not completed15455138
Withdrew: Adverse event0110001
Withdrew: Protocol violation0001000
Withdrew: Withdrawal by subject1321501
Withdrew: Lost to follow-up0011010
Withdrew: Physician decision0100000
Withdrew: Pregnancy0001000
Withdrew: Study terminated by sponsor00010126

Outcome measures

PrimaryNumber of Participants Who Experienced at Least One Adverse Event

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to 32 Weeks
Reported as:
Number · participants
Number of Participants Who Experienced at Least One Adverse Event
participantsPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: Placebo
Number of Participants Who Experienced at Least One Adverse Event86677107
PrimaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event

An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.

Time frame:
Up to 12 Weeks
Reported as:
Number · participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
participantsPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: Placebo
Number of Participants Who Discontinued Study Drug Due to an Adverse Event0110001
PrimaryChange From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 1

Reduction from baseline in EASI at Week 12 (interim analysis data). The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).

Time frame:
Baseline, Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 1
Score on a scalePart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)
Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 1-5.77 ± 6.17-8.40 ± 9.39-10.20 ± 7.23-7.78 ± 8.35-0.38 ± 6.37
Statistical analysis
  • Part 1: MK-8226 3 mg/kg vs Part 1: Placebo (Pooled) · Constrained longitudinal data analysis · p = 0.015 · Mean difference (final values): -9.82 · 95% CI -16.87 to -2.77
SecondaryPlasma Chemokine (C-C Motif) Ligand 17 (CCL17) Level in Study Part 2

CCL17 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL17 are increased in allergic disease states.

Time frame:
Baseline, 48 Hours, Week 2, Week 4, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryPlasma Chemokine (C-C Motif) Ligand 22 (CCL22) Level in Study Part 2

CCL22 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL22 are increased in allergic disease states.

Time frame:
Baseline, 48 Hours, Week 2, Week 4, Week 12, Week 16

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve of MK-8226 From Time 0 to Tau (AUC0-tau) Following Multiple Intravenous Dose Administration

AUC(0-tau) defined as AUC from time zero to tau where tau is the dosing interval (312 hours) was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

Time frame:
Days 1, 3, 5, 9, 14, 70, 72, 74, 84
Reported as:
Geometric mean · μg*hr/mL
Area Under the Concentration-time Curve of MK-8226 From Time 0 to Tau (AUC0-tau) Following Multiple Intravenous Dose Administration
μg*hr/mLPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kg
Week 1 (n=9,7,8,10)1000 ± 18.23300 ± 29.39300 ± 19.131400 ± 11.2
Week 10 (n=8,5,6,6)2310 ± 118530 ± 15.421100 ± 28.882100 ± 16.2
SecondaryAUC From Time 0 to Last Measurement (AUC0-last) of MK-8226 Following Multiple Intravenous Dose Administration

AUC0-last defined as AUC up to the last measured concentration was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

Time frame:
Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224
Reported as:
Geometric mean · μg*hr/mL
AUC From Time 0 to Last Measurement (AUC0-last) of MK-8226 Following Multiple Intravenous Dose Administration
μg*hr/mLPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kg
AUC From Time 0 to Last Measurement (AUC0-last) of MK-8226 Following Multiple Intravenous Dose Administration6460 ± 34.322600 ± 65.847100 ± 97.2264000 ± 25.2
SecondaryMaximum Serum Concentration (Cmax) of MK-8226 Following Multiple Dose Intravenous Administration

Cmax was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

Time frame:
Days 1, 3, 5, 9, 14, 70, 72, 74, 84
Reported as:
Geometric mean · μg/mL
Maximum Serum Concentration (Cmax) of MK-8226 Following Multiple Dose Intravenous Administration
μg/mLPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kg
Week 1 (n=9,8,8,10)7.12 ± 21.921.6 ± 26.060.3 ± 18.0200 ± 12.1
Week 10 (n=8,6,6,6)11.7 ± 9.6342.4 ± 20.1106 ± 19.6398 ± 17.1
SecondaryClearance (CL) of MK-8226 Following Multiple Dose Intravenous Administration

CL, the volume of plasma cleared of drug per unit time, was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 28 (incl. predose), 42 (incl. predose), 56 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

Time frame:
Days 1, 3, 5, 9, 14, 28, 42, 56, 70, 72, 74, 84
Reported as:
Geometric mean · mL/day/kg
Clearance (CL) of MK-8226 Following Multiple Dose Intravenous Administration
mL/day/kgPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kg
Clearance (CL) of MK-8226 Following Multiple Dose Intravenous Administration3.04 ± 112.81 ± 15.43.33 ± 28.82.9 ± 16.2
SecondaryVolume of Distribution (Vd) of MK-8226 Following Multiple Intravenous Administration

Vd, a theoretical approximation of degree to which the drug distributes in body tissue rather than plasma (higher Vd indicates greater tissue distribution), was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

Time frame:
Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224
Reported as:
Geometric mean · mL/kg
Volume of Distribution (Vd) of MK-8226 Following Multiple Intravenous Administration
mL/kgPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kg
Volume of Distribution (Vd) of MK-8226 Following Multiple Intravenous Administration103 ± 27.6122 ± 26.8102 ± 62.1120 ± 25.3
SecondaryTerminal Half Life (t1/2) of MK-8226 Following Multiple Dose Intravenous Administration

t1/2, the time needed for the concentration of drug to reach half the initial concentration, was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.

Time frame:
Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224
Reported as:
Geometric mean · days
Terminal Half Life (t1/2) of MK-8226 Following Multiple Dose Intravenous Administration
daysPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kg
Terminal Half Life (t1/2) of MK-8226 Following Multiple Dose Intravenous Administration23.6 ± 33.530 ± 15.924.7 ± 51.328.7 ± 15.7
SecondaryChange From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 2

The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).

Time frame:
Baseline, Week 4, Week 8, Week 24

No measurements were reported for this outcome.

SecondaryPercentage of Participants With an Investigator Global Assessment (IGA) Score of Clear or Almost Clear in Study Part 2

Percentage of participants achieving an IGA of atopic dermatitis of "clear-0" or "almost clear-1". The IGA is a six-point scale measuring the severity of disease at time of physical examination of the participant by the physician. The IGA is scored 0 (Clear) to 5 (Very severe disease).

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Scoring Atopic Dermatitis Scale (SCORAD) in Study Part 2

The SCORAD index scale combines 1) intensity of six lesion characteristics (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness) as assessed by the physician on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities) along with 2) subjective symptoms of pruritus and sleep disturbance as reported by the patient on a visual analog scale (VAS) from 1 to 10 cm (increasing severity). Physician assessment of affected areas in each region is made as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The final SCORAD index score, ranging from 0 (absent disease) to 103 (severe disease), is calculated according to the weighted formula: (0.2 x area) + (3.5 x \[sum of intensity score for each of the 6 items\]) + participant's subjective score.

Time frame:
Baseline, Week 4, Week 12, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Participant Pruritus in Study Part 2

Skin pruritus (itching) is a typical characteristic of atopic dermatitis. Participant subjective assessment of pruritus (component of SCORAD) is rated on a VAS ranging from 1 to 10 cm (increasing severity).

Time frame:
Baseline, Week 4, Week 12, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Participant Sleep Disturbance in Study Part 2

Sleep disturbance (sleep loss, disruption, or interference) due to unremitting pruritus and other causes is a quality of life issue in moderate to severe atopic dermatitis. Participant subjective assessment of sleep disturbance (component of SCORAD) over the past 3 days is rated on a VAS ranging from 1 to 10 cm (increasing severity).

Time frame:
Baseline, Week 4, Week 12, Week 24

No measurements were reported for this outcome.

SecondaryNumber of Participants Requiring As-Needed Oral Antihistamines as Rescue Medication in Study Part 2

Oral antihistamines (i.e., diphenhydramine, acrivastine fenistil) were provided as as-needed rescue medication for severe pruritus.

Time frame:
Up to Week 12

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in the Participant's Global Impression of Disease Status in Study Part 2

Participant subjective impression of improvement of his/her disease condition is scored on a six-point scale: 0 (Clear) to 5 (Very severe disease).

Time frame:
Baseline, Week 4, Week 12, Week 24

No measurements were reported for this outcome.

SecondaryPercentage of Participants With >=50% Improvement in EASI Score

The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).

Time frame:
Baseline, Week 12, Week 24

No measurements were reported for this outcome.

SecondaryNumber of Participants Positive for Anti-Drug Antibody (ADA) Formation

Testing for ADA positivity and neutralizing response and antibody titre quantification are performed with blood (serum) samples collected at baseline (Day 1 predose) and Days 14, 28, 42, 56, 74, 112, and 224. Neutralizing response refers to ADA neutralizing interference with study drug assessed in vitro. Non-Treatment emergent ADA refers to presence of ADAs (as determined by assay) in the absence of treatment with study drug (i.e., at predose).

Time frame:
Days 1 (predose) and Days 14, 28, 42, 56, 74, 112, and 224
Reported as:
Number · Participants
Number of Participants Positive for Anti-Drug Antibody (ADA) Formation
ParticipantsPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: Placebo
Non Treatment emergent ADA positive0100—00
Treatment emergent ADA positive0010—20
ADA positive: Max titer 1:100000—00
ADA positive: Max titer 1:500010—10
ADA positive: Neutralizing response positive0010—10

Adverse events

Collected over Up to 32 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: MK-8226 0.3 mg/kg—0/9 (0%)8/9 (88.9%)
Part 1: MK-8226 1 mg/kg—0/9 (0%)6/9 (66.7%)
Part 1: MK-8226 3 mg/kg—0/8 (0%)6/8 (75%)
Part 1: MK-8226 10 mg/kg—1/10 (10%)7/10 (70%)
Part 1: Placebo (Pooled)—0/8 (0%)7/8 (87.5%)
Part 2: MK-8226 3 mg/kg—0/13 (0%)10/13 (76.9%)
Part 2: Placebo—1/8 (12.5%)7/8 (87.5%)
Most frequent serious events
Most frequent serious events
EventPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: Placebo
ErysipelasInfections and infestations0/90/90/80/100/80/131/8
Abortion inducedSurgical and medical procedures0/90/90/81/100/80/130/8
Most frequent other events
Showing 10 of 78
Most frequent other events
EventPart 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: Placebo
NasopharyngitisInfections and infestations4/91/91/83/102/84/132/8
Skin infectionInfections and infestations0/90/92/80/100/80/130/8
Urinary tract infectionInfections and infestations0/90/90/80/100/80/132/8
HeadacheNervous system disorders2/90/91/81/101/83/132/8
Dermatitis atopicSkin and subcutaneous tissue disorders0/91/91/81/100/83/131/8
Abdominal painGastrointestinal disorders0/90/91/80/100/80/130/8
FatigueGeneral disorders1/91/91/80/100/80/130/8
Gravitational oedemaGeneral disorders0/90/90/80/101/80/130/8
Peripheral swellingGeneral disorders0/90/90/80/101/80/130/8
BronchitisInfections and infestations1/91/90/80/100/80/131/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: PlaceboTotal
<=18 years00000000
Between 18 and 65 years89810813864
>=65 years10000001
Age, Continuous
Age, Continuous(years)Part 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: PlaceboTotal
Mean49.0 ± 11.830.8 ± 13.441.6 ± 12.634.7 ± 10.237.8 ± 14.238.3 ± 11.533.9 ± 12.938.0 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: MK-8226 0.3 mg/kgPart 1: MK-8226 1 mg/kgPart 1: MK-8226 3 mg/kgPart 1: MK-8226 10 mg/kgPart 1: Placebo (Pooled)Part 2: MK-8226 3 mg/kgPart 2: PlaceboTotal
Female424658332
Male574435533
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2012 to primary completion in Oct 2014, 21 months.

Results were first posted in Jun 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2012
First posted
Nov 22, 2012
StartActual
Dec 21, 2012
Primary completionActual
Oct 20, 2014
CompletionActual
Oct 20, 2014
Results first posted
Jun 9, 2016
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01732510
Responsible party
Sponsor
First posted
Nov 22, 2012
Start date
Dec 21, 2012
Primary completion
Oct 20, 2014
Completion
Oct 20, 2014
Results posted
Jun 9, 2016
Last update
Mar 15, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solrikitug

Start the discussion